• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

FDA approves topical solution for low testosterone

Article

The FDA has approved testosterone topical solution CIII (Axiron) for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.

The FDA has approved testosterone topical solution CIII (Axiron) for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.

The treatment is the first testosterone topical solution approved for application via an armpit applicator, according to manufacturers Eli Lilly and Co. and Acrux.

A phase III multicenter, open-label, 120-day clinical study demonstrated that 84% of men who completed the study achieved average serum testosterone concentration within the normal range of 300 to 1,050 ng/dL. Additionally, after 120 days of treatment, 75% of responding patients finished the study on the recommended starting dose of 60 mg.

The most common adverse reactions (incidence greater than 4%) in the study were skin application site reactions, increased red blood cell count, headache, diarrhea, vomiting, and an increase in PSA.

Related Videos
Video 1 "Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC"
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
David Barquin, MD, answers a question during a Zoom video interview
Alexandra Tabakin, MD, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.